Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:51:23 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:ABUS - ARBUTUS BIOPHARMA CORP - https://www.arbutusbio.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ABUS - Q0.13.53·182.002.03.84+0.174.62,562.58,9329,7983.84  3.90  3.675.10  2.70519:25:13Nov 1315 min RT 2¢

Recent Trades - Last 10 of 9798
Time ETExPriceChangeVolume
19:25:13Q3.970.30344
17:05:29Q3.880.2110
16:33:47Q3.880.2110
16:31:11Q3.8990.22915
16:28:48Q3.89620.22625
16:26:58Q3.89620.22625
16:10:04Q3.840.171
16:10:04Q3.840.171
16:10:03Q3.840.171
16:10:03Q3.840.171

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-11-13 11:06U:ABUSSEDAR Interim Financial StatementsSEDAR Interim MD & A
2025-11-13 07:30U:ABUSNews ReleaseArbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-10-07 08:00U:ABUSNews ReleaseArbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting(TM) 2025
2025-08-06 12:51U:ABUSSEDAR Interim MD & ASEDAR Interim MD & A
2025-08-06 12:46U:ABUSSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2025-08-06 07:30U:ABUSNews ReleaseArbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2025-06-25 07:30U:ABUSNews ReleaseArbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
2025-05-15 15:08U:ABUSSEDAR Interim Financial StatementsSEDAR Interim MD & A
2025-05-14 07:30U:ABUSNews ReleaseArbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
2025-05-07 02:01U:ABUSNews ReleaseArbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
2025-04-23 02:01U:ABUSNews ReleaseArbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
2025-03-27 07:30U:ABUSNews ReleaseArbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
2025-03-27 04:48U:ABUSSEDAR Annual ReportSEDAR MD & A
2025-03-27 04:43U:ABUSSEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2025-03-03 09:15U:ABUSNews ReleaseGenevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
2025-02-25 07:00U:ABUSNews ReleaseArbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO